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There is currently no biochemical test for detection of early-stage osteoarthritis (eOA). Tests for early-stage
rheumatoid arthritis (eRA) such as rheumatoid factor (RF) and anti–cyclic citrullinated peptide (CCP)
antibodies require refinement to improve clinical utility.We developed robust mass spectrometric methods
to quantify citrullinated protein (CP) and free hydroxyproline in body fluids.We detected CP in the plasma
of healthy subjects and surprisingly found that CPwas increased in both patients with eOAand eRAwhereas
anti–CCP antibodies were predominantly present in eRA. A 4-class diagnostic algorithm combining
plasma/serum CP, anti-CCP antibody and hydroxyproline applied to a cohort gave specific and sensitive
detection and discrimination of eOA, eRA, other non-RA inflammatory joint diseases and good skeletal
health. This provides a first-in-class plasma/serum-based biochemical assay for diagnosis and type
discrimination of early-stage arthritis to facilitate improved treatment and patient outcomes, exploiting
citrullinated protein and related differential autoimmunity.
M
usculoskeletal disease including osteoarthritis (OA) and rheumatoid arthritis (RA) is the most common
cause of chronic disability worldwide and is increasingly important in current ageing populations. It is a
major contributor to global disability adjusted life years1. Severe life impairment may be prevented if
decline inmusculoskeletal health and development of OA and RA are identified and treated in the early stages. An
inexpensive, minimally invasive biochemical test which preferably detects and distinguishes common types of
arthritis at the early stage is required. Magnetic resonance imaging (MRI) techniques have been developed for
early-stage evaluation of cartilage damage in OA. They have approximately 70% sensitivity and 90% specificity
compared to reference diagnosis by arthroscopy, thus lending more utility to excluding OA diagnosis when
otherwise suspected than detecting new OA2. MRI techniques require expensive instrumentation time and
facilities as well as being contraindicated in certain populations who have implanted devices such as pacemakers
or aneurysm coils. Early biochemical tests for detection of established RA were based on measurement of RF
which in current form have reported sensitivity and specificity of 63% and 94% respectively for established or
advanced disease3. RF is often negative with eRA. The anti-CCP antibody test is used for early-stage detection of
RA and has sensitivity of 61%4. There is currently no simple biochemical test to detect eOA and to discriminate
different types of early-stage arthritis.
The clinical presence of anti-CCP antibodies, antibodies which bind to synthetic cyclic citrullinated peptide,
are considered to reflect immunogenicity of endogenous citrullinated proteins (CPs) but the diagnostic utility of
CPs has hitherto been little explored. The formation of citrulline residues in proteins occurs by a post-
translational modification of arginine residues catalysed by members of the peptidylarginine deiminase (PAD)
family of enzymes5 (Figure 1a). This process is considered to be a marker of inflammation. CPs are immunogenic
in vivo and are involved in autophagic presentation of antigens5. A further biochemical marker historically linked
to skeletal health and disease is 4-hydroxyproline (Hyp). Plasma Hyp is considered to be a marker of bone
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turnover and resorption6. Recent clinical studies suggest 62% of the
variation in plasma free Hyp relates to bone metabolism7. We
hypothesised that changes in plasma CP and Hyp, combined with
anti-CCP antibody test, would provide improved diagnostic power
over current standard techniques for diagnosis of early-stage arthritis.
Methods for robust quantitation of CP and Hyp are currently lacking.
To test our hypothesis we developed a robust stable isotopic dilution
analysis mass spectrometric method for the detection of CP and Hyp.
We describe herein robust quantitation of total CP and free Hyp
and show that CP is surprisingly present at high levels in both eOA
and eRA, and when estimates of CP and plasma Hyp are combined
with the anti-CCP antibody test in a diagnostic algorithm using
machine learning techniques, early-stage arthritic diseases from con-
trol group can be readily detected and distinguished.
Results
Wedeveloped a stable isotopic dilution analysis liquid chromatography-
tandem mass spectrometry (LC-MS/MS) protocol for the quantita-
tion of total CP in plasma. Plasma, serum or synovial fluid protein is
separated from free citrulline by microspin diafiltration, digested to
component amino acids by exhaustive enzymatic hydrolysis and
citrulline released from CPs quantified. CP contents of plasma or
serum protein are normalised to arginine content and given as
mmol/mol arg. The method had high specificity, good linearity of
response from 62–50,000 fmol (R2 5 0.9999) and high sensitivity -
the limit of detection was 62 fmol, equivalent to 0.006 mmol/mol arg
in plasma protein under assay conditions (Figure 1b and
Supplementary Table S1). CP was detected and quantified in plasma
protein of healthy people. Plasma CP was 0.053 (0.043–0.091) mmol/
mol arg (n 5 16) and correlated positively with plasma Hyp (r 5
0.63, P, 0.05). CP was increased 4-fold in serum protein of patients
with eRA and surprisingly was even higher, increased 5-fold, in
patients with eOA, with respect to healthy controls. CP was not
increased in serum of patients with inflammatory arthritis other than
RA (non-RA) (Figure 1c). There was no association of increased CP
with smoking (ever versus never smoked), inflammatory markers
(plasma/serum C-reactive protein concentration and erythrocyte
sedimentation rate) or alcohol consumption. Herein CP content of
serum samples for eRA and non-RA are compared with plasma of
other study groups. Serum is comparable to plasma as a sample
matrix as the major protein lost during clot formation, fibrinogen,
has relatively low citrulline content and concentration in plasma8,
equivalent to,0.001 mmol/mol arg in CP analysis herein. Replicate
analyses gave a mean estimate range of 14% (n 5 12) and Bland-
Altman plot indicated no proportional bias.
Free Hyp was analysed in plasma, serum and synovial fluid by
stable isotopic dilution analysis LC-MS/MS. The method had high
specificity, good linearity of response from 0.1–50 pmol and high
sensitivity (R2 5 0.9997). The limit of detection was 102 fmol
(Supplementary Table S1). The median concentration of Hyp in
Figure 1 | (a) Formation of citrullinated protein. (b) Analysis of citrullinated protein. Detection and quantitation of citrulline by stable isotopic dilution
analysis LC-MS/MS. Left-hand panel – MRM chromatogram of citrulline in plasma protein digest from patient with eOA, middle panel - MRM
chromatogram of [5-13C-4,4,5,5-2H4]citrulline internal standard (5 pmol), right-hand panel – calibration curve of citrulline/[5-
13C-4,4,5,5-2H4]citrulline
MRM chromatographic peak area ratio against citrulline standard (pmol). (c) Citrullinated protein (CP) and (d) hydroxyproline (Hyp) in early-stage
arthritis and healthy human subjects. Samples were plasma for Control (n 5 16) and eOA (n 5 16) and serum for eRA (n 5 10) and non-RA (n 5 10).
Significance: *, ** and ***, P , 0.05, P , 0.01 and P , 0.001 with respect to control (healthy people). Data are median (lower – upper quartile).
(e) Discrimination of study groups by discrete patterns of CP, Hyp and Anti-CCP antibody response. Each darkened shade presents approximately
a 2-fold increase.
www.nature.com/scientificreports
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plasma of healthy people was 1.26 (0.86–1.86) mM. Plasma Hyp was
increased 44% in eOA and 58% in non-RA but not increased in eRA
with respect to healthy controls (Figure 1d). Most patients with eRA
were positive for anti-CCP antibodies whereas healthy controls, eOA
and non-RA were all negative. For eRA, plasma CP in patients pos-
itive for anti–CCP antibodies was significantly higher than plasma
CP of healthy controls - 0.259 (0.186–0.607) mmol/mol arg, P, 0.01
but not in patients negative for anti–CCP antibodies. By this vari-
ation of analytes - plasma/serum CP, Hyp and anti-CCP antibody
positivity, a distinctive analyte pattern emerged for each study group
(Figure 1e). This is exploited in a diagnostic algorithm developed
using a machine learning analysis approach. Replicate analyses gave
a mean estimate range of 15% (n 5 12) and Bland-Altman plot
indicated no proportional bias.
We performed a machine learning analysis on subject groups with
and without early-stage arthritis to assess the predictive power of the
measured biomarkers. In all cases, the predictive algorithms were
trained on the training data set, before being used to predict the
disease class for each sample in the test data set (Figure 2a). The
objective was to distinguish simultaneously between four groups:
healthy control, eOA, eRA and non-RA – particularly useful in the
clinical context. We took two approaches: firstly, we used a set of 4
one-versus-all classification tasks, and secondly we used a single
overall analysis using multinomial logistic regression. In the one-
versus-all analyses, we ran Random Forests9 and GLMNET clas-
sification algorithms10, as well as an ensemble11 that combined both
of these in equal proportions. We also considered Gaussian process,
Generalised Boosting model, and K-nearest-neighbour algorithms
but found these to be no better than GLMNET, so we do not report
those results here. In all analyses, we use the panel of three biomar-
kers given above, plasma/serum CP, Hyp and anti-CCP antibody
positivity, and subject age and gender. The outcome of each analysis
was to assign, for each test set sample, a set of four probabilities
corresponding to each of the four disease/control groups. The pre-
dicted group is then the one for which the probability is highest. The
test data were held separate from the algorithm training and no
algorithm settings were adjusted after generating the test set results
– providing for a rigorous estimate of predictive performance on
Figure 2 | Training and validation of a multiclass algorithm for detection and discrimination of early stage osteoarthritis, rheumatoid arthritis, other
inflammatory joint disease from healthy subjects. (a) Training set and test set study groups. Receiver operating characteristic curves in the test set for
detection of: (b) healthy controls (n 5 37), (c) eOA (n 5 30), (d) eRA (n 5 35) and (e) non-RA (n 5 32).
www.nature.com/scientificreports
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previously unseen cases. We performed Leave-One-Out (LOO)
cross-validation analyses, comparing in turn each of the classes with
the other three, thereby providing estimation of the predictive per-
formance of each machine learning algorithm, when trained on the
training set data. The clinical characteristics of training and test set
study groups are given in Table 1. GLMNET algorithm gave the best
outcome through training and test sets. Applying the algorithm for 4
classes, for which random assignment sensitivity and specificity
50.25, the GLMNET algorithm gave sensitivities of 0.41–0.73 for
groups excluding non-RA and specificities of 0.75–0.91 for all groups
and highest combined F-measure (P 5 3.5 3 1027) in the test set
validation – Table 2. The outcome is presented also as a confusion
matrix – Table 3. A limitation of the study was relatively small num-
bers of cases on the eRA and non-RA study groups in the training set.
To assess the impact of this, further cross validation was performed
whereby the training and test set subjects were combined and then
67% of the subjects from each group were selected randomly as a
surrogate training set and the remaining 33% of subjects as a surrog-
ate test set. The re-assessed GLMNET analysis gave improved dia-
gnostic performance - sensitivities of 0.67–0.76 for groups excluding
non-RA and specificities of 0.77–1.00 for all groups and highest
combined F-measure (P 5 2.9 3 10211), confirming and improving
the security of the 4-class diagnosis outcomes – Table S2. Receiver
operating characteristic (ROC) curves gave area under curves (mean
(95% confidence intervals): healthy control 0.77 (0.64–0.90), eOA
0.86 (0.75–0.97), eRA 0.98 (0.95–1.00), and non-RA 0.65 (0.50–0.81)
– Figure 2, b.–d.
We also compared CP and Hyp in plasma or serum and synovial
fluid of early and advanced stages of OA and RA. In eOA, there was a
negative gradient of CP from plasma into synovial fluid whereas in
aOA this was reversed and there was a strong positive gradient from
plasma to synovial fluid. Plasma CP was decreased 73% in aOA,
compared to plasma CP in eOA whereas synovial fluid CP was
increased in 72% in aOA compared to synovial fluid CP in eOA
(Figure 3a). In eRA, there was no significant difference in CP content
of serum and synovial fluid whereas in aRA there was a strong
positive gradient from plasma to synovial fluid. Plasma CP was
decreased 59% in aRA, compared to serum CP in eRA whereas
plasma and synovial fluid CP in aRA were similar levels
(Figure 3b). Serum CP correlated positively with synovial fluid CP
in patients with eRA (r 5 0.81, P , 0.05) but not in patients with
aRA. There were strong positive gradients of Hyp from plasma to
synovial fluid in both eOA and aOA but no significant difference of
plasma or synovial fluid Hyp in aOA compared to eOA (Figure 3c).
In eRA there was a strong positive gradient of Hyp from serum to
synovial fluid but not in aRA (Figure 3d). Plasma Hyp correlated
positively with Hyp in synovial fluid in eOA, r 5 0.70, P, 0.01 and
aOA, r 5 0.56, P , 0.05; and serum Hyp correlated positively with
synovial fluid Hyp in eRA (r 5 0.88, P , 0.001).
Discussion
Detecting and distinguishing different types of early-stage arthritis is
unachievable routinely – if attempted, it requires arthroscopy orMRI
for detection of eOA in combination with immunochemical tests to
distinguish eRA. There is no clinically established method to detect
eOA; radiography remains the method of choice for staging OA but
shows little or no changes in eOA. Hence when OA is confirmed
significant pain, discomfort and damage to the joint is already pre-
sent. Diagnosis of eRA is made by immunochemical tests, often
before damage to the joint occurs. The diagnostic outcome described
herein, combination of plasma/serum CP, Hyp and anti-CCP anti-
body in a diagnostic algorithm, is therefore a first-in-class technique
providing for biochemical diagnosis and discrimination of eOA, eRA
and non-RA and healthy controls. It requires minimally invasive,
non-expert sampling and analysis, and has relatively high through-
put and low cost. Biochemical tests for the detection of eOA haveT
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been proposed previously12 but our test provides both early detection
and discrimination of type of arthritis by exploiting the CP epitope
shown herein for the first time to be common in relatively high
abundance in both early-stage OA and RA with autoimmunity
restricted to early-stage RA. The strengths of using the machine
learning approach in producing the diagnostic algorithm are that it
provides a data-driven discovery of complex combinations of inde-
pendent variables or features and their relative influence on the
dependent variable of interest (diagnosis of early-stage type of arth-
ritis) by logical, step-wise analysis without preconception and bias.
The limitations are access to restricted application specific data –
variables recorded and dataset size, and as a post hoc analysis all data
collectionmust be completed before implementation. It also requires
expertise for awareness of variables available for inclusion in the
analysis – which applies to other types of data analysis.
The surprising and remarkable biochemical finding of this study is
increased levels of plasma CP in eOA. Increased CP was found in
serum of eRA but this was suspected with regard to the high preval-
ence of anti-CCP antibody positivity in eRA. Also remarkable was
the higher CP concentration in plasma than in synovial fluid of
patients with eOA and reversal of this in patients with aOA.
Recent research has suggested movement of plasma proteins into
the synovium occurs in eOA and contributes to an inflammatory
response13. It is now accepted that there is an inflammatory com-
ponent of OA with a decrease in inflammatory mediators in
advanced disease14. Inflammatory mechanisms linked to CP forma-
tionmay be a component of this and compartmentalised between the
vasculature and synovium. PAD2 and PAD4 were detected in syn-
ovial tissue of patients with OA15 and dysfunction of autophagy has
been linked to cartilage destruction in OA16. Multi-compartmental
expression and activity of PADs, plasma and synovial fluid CPs and
links to dysfunctional autophagy and cartilage loss now require
investigation.
Autoimmunity to CP is important in the pathogenesis of RA and
underlies the diagnostic utility of anti-CCP antibody measurement
for eRA5.We found high levels of serumCP in patients with eRA and
association of this with anti-CCP antibodies, consistent with forma-
tion and immunogenicity of CPs. In eRA, similar concentrations of
CP in serum and synovial fluid are consistent with equilibration of
CP between plasma and synovial fluid in vivo and/or similar factors
influencing CP formation in both compartments. PAD2 and PAD4
enzymes have been detected in synovial tissue and also lymphocytes
and monocytes in patients with RA15 and are likely drivers for CP
formation in RA. The lack of association of CP with smoking in eRA
may be due to the relatively old age of onset of RA studied –mean age
of 65 yrs in the training set and 60 yrs in the test set. Recent risk
prediction models of large cohort studies indicate that for onset of
RA at age 60–65 the risk of developing RA is similar in never and ever
smokers in both males and females17.
The presence of CPs in plasma of healthy people implicates PADs
in pre-symptomatic low grade inflammation which may be activated
and increased in susceptible individuals and environments.
Autoimmunity to several CPs has been detected prior to develop-
ment of RA18 and is linked to bone resorption19. The correlation of
CPwith Hyp in plasma of healthy subjects found hereinmay betray a
link of protein citrullination to bone resorption of pre-symptomatic
arthropathy.
The detection and quantitation of CP in plasma/serum, synovial
fluid and elsewhere poses a significant analytical challenge. The
citrulline residue epitope in proteins occurs in trace amounts
(0.1–0.01% arginine residues) in the presence of 10–50 fold higher
concentration of free, dialyzable citrulline - a metabolite of the urea
cycle and co-product of nitric oxide synthases20. The reference
method for quantitation of trace amino acid residues such as citrul-
line residues in CPs is hydrolysis of proteins to component amino
acids and quantitation by stable isotopic dilution analysis LC-MS/
MS. Enzymatic digestion is used to avoid compromise of analyte
content by harsh conditions for hydrolysis during pre-analytic pro-
cessing21. The analysis of CP herein provides an estimate of total CP
– the sum of citrulline residues in all proteins of plasma or synovial
fluid. Individual CPs have been identified by mass spectrometry
proteomics but approaches to date have lacked robust quantitation
and mass spectrometric detection of the citrulline residue22. Stable
isotope-dilution mass spectrometry methods such as this are con-
sidered reference methods of extremely high accuracy as they have
high specificity to analyte for detection response and all sample
matrix-related effects affect target analyte and stable isotope-
labelled internal standard in a similar manner23. The assay has
good day-to-day reproducibility and sample stability during batch
analysis.
Robust measurement of free Hyp in plasma was also achieved
herein. This gave lower estimates in plasma and synovial fluid than
those using other techniques24–26, which is likely due to the high
specificity of stable isotopic dilution analysis LC-MS/MS.
Limitations of the study are the requirement for further clinical
validation of the diagnostic algorithm and the cross-sectional design
of the study. In further studies validation with larger subject groups
and evaluation of the link of the diagnostic output to progression to
advanced-stage arthritis are important issues to address. Selection for
eOA subjects from subjects with new onset knee pain and
Outerbridge classification low grade changes and joint changes on
arthroscopic investigation consistent with eOA may have included
some subjects with other features – such as synovial inflammation
(found in some eOA27) or bone marrow lesions.
Table 2 | Multiclass algorithm outcome with test set cohort using the GLMNET algorithm
Control eOA eRA non-RA
nCorrect 15/37 22/30 20/35 8/32
Sensitivity 0.41 (0.25–0.58) 0.73 (0.54–0.88) 0.57 (0.39–0.74) 0.25 (0.11–0.43)
Specificity 0.75 (0.65–0.83) 0.87 (0.78–0.92) 0.91 (0.83–0.96) 0.76 (0.68–0.85)
F-Measure 0.54 0.78 0.68 0.36
Data are 95% CI for sensitivity and specificity given in brackets. Predictive performance of the algorithm trained using the training data set and predicting for the test data set. We emphasise ambitious nature
of a multiclass analysis of this type. In order to correctly identify a given case, we must discriminate between three additional, potentially very different conditions, as opposed to just one (in the standard
classification case). For example, if one were to assign cases at random to disease groups, one would only achieve a 25% success rate. The above predictive performance should be considered with this in
mind.
Table 3 | Confusion matrix for GLMNET multiclass algorithm
Predicted class
Control Early OA Early RA non-RA
Clinical class Control 15 3 9 12
eOA 3 22 4 5
eRA 1 1 20 7
non-RA 18 4 2 8
www.nature.com/scientificreports
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In summary, we present a multi-class diagnosis algorithm to meet
the unmet clinical need for early-stage diagnosis and typing of arth-
ritis. Combination of plasma CP, anti-CCP antibody and Hyp gave
specific and sensitive detection and discrimination of eOA, eRA,
non-RA and good skeletal health, exploiting the discovery of CP in
eOA, low levels in healthy people and differential autoimmunity of
CP in eOA and eRA.
Methods
Patients, healthy subjects and sampling. Patients with longstanding history or
established severe, advanced OA (aOA) were recruited at the Department of
Rheumatology, Ipswich Hospital NHS Trust, U.K. and Orthopaedic Clinics,
University Hospital Coventry & Warwickshire, Coventry, U.K. Patients were
undergoing therapeutic knee aspiration and corticosteroid instillation or undergoing
total knee replacement due to longstanding symptoms of OA with corresponding
radiographic changes. Patients with early-stage OA (eOA) were also recruited at the
latter Clinic presenting with new onset knee pain. All patients with eOA had normal
radiographs of the symptomatic knee and were undergoing routine exploratory
arthroscopy. Macroscopic findings on arthroscopy were classified according to the
Outerbridge classification. Patients found to have changes (Outerbridge grade I/II)
during routine arthroscopy were recruited for eOA. Patients with advanced
rheumatoid arthritis (aRA) were recruited at the Department of Rheumatology,
Ipswich Hospital NHS Trust, U.K. and Department of Rheumatology, Royal Devon
and Exeter NHS Foundation Trust, Exeter, UK. Patients with early-stage arthritis
(within 5 months of the onset of symptoms of inflammatory arthritis) were recruited
at the Rapid Access Rheumatology Clinic, City Hospital, Birmingham, U.K. Synovial
fluid and peripheral venous blood samples were collected at initial presentation.
Diagnostic outcomes were determined at follow-up as non-RA [reactive arthritis (6),
pseudogout (1), and unclassified (3)] or early rheumatoid arthritis (eRA). Normal
healthy control subjects were recruited according to the following criteria: inclusion
criteria - no history of joint symptoms with no arthritic disease or other morbidity;
and exclusion criteria - a history of knee injury or knee pain in either knee, taking
medication - excepting oral contraceptives and vitamins, and any abnormality at
physical examination of the knee. Peripheral venous blood samples from healthy
people and subjects with eOA were collected after overnight fasting, as was synovial
fluid of eOA study group. Samples were collected in the non-fasted state for eRA, non-
RA, aOA and aRA study groups. For analytes studied herein, diurnal variation of
serum Hyp had a range of 20%28 and plasma CP of healthy subjects was not changed
significantly when collected in fasted or non-fasted states (n5 30). Peripheral venous
blood samples were collected with EDTA anti-coagulant from patients pre-
operatively and synovial fluid obtained intraoperatively from patients, as appropriate.
Blood and synovial fluid were centrifuged (2000 g, 10 min) and the resulting plasma
and synovial fluid supernatant removed and stored at 280uC until analysis. Synovial
fluid was aspirated from the knee joints of patients and stored at280uCuntil analysis.
Subject characteristics are given in Table 1. Ethical approval for this work was
sought and obtained from local ethics committees at Ipswich Hospital NHS Trust,
U.K., West Midlands Regional Ethics Committee, U.K., and South West – Exeter
Regional Ethics Committee, U.K. The collection of samples from patients and healthy
subjects with informed consent and use of them were approved by the local medical
ethics committee and were conducted in accordance with the Declaration of
Helsinki.
Analysis of citrullinated protein. The content of citrulline (and arginine) residues in
plasma/serum and synovial proteins was quantified in exhaustive enzymatic digests
by stable isotopic dilution analysis LC-MS/MS29. Plasma or synovial fluid (100 ml)
was diluted 5-fold with water and washed by 4 cycles of concentration to 50 ml and
dilution to 500 ml with water over a microspin ultrafilter (10 kDa cut-off) at 4uC. The
final washed protein (100 ml) was delipidated by extraction 3-times with an equal
volume of water-saturated ether. Residual ether was removed in a centrifugal
evaporator and protein concentration determined by Bradford method. For
enzymatic hydrolysis, an aliquot of protein (100 mg in 20 ml water, free citrulline
,62 fmol or ,0.002 mmol/mol arg) was mixed with 100 mM HCl (10 ml), pepsin
(2 mg/ml in 20 mMHCl; 5 ml) and thymol (2 mg/ml in 20 mMHCl; 5 ml) in HPLC
vials with fused glass inserts. The samples were gassed with argon by 3 cycles of
placing under vacuum (20 mmHg, 2 min) and re-filling with argon in a centrifugal
evaporator. Samples were incubated at 37uC for 24 h. The samples were then
neutralized and buffered at pH 7.4 by the addition of firstly 12.5 ml 100 mM
potassium phosphate buffer, pH 7.4, and then 5 ml 260 mM KOH. Pronase E
(2 mg/ml in 10 mM potassium phosphate buffer, pH 7.4; 5 ml) and penicillin-
streptomycin solution (1000 units/ml and 1 mg/ml respectively; 5 ml) was added and
the samples were incubated at 37uC for a further 24 h. Finally aminopeptidase (2 mg/
ml in 10 mM potassium phosphate buffer, pH 7.4; 5 ml) and prolidase solution
(2 mg/ml in 10 mM potassium phosphate buffer, pH 7.4; 5 ml) were added and the
samples incubated at 37uC for a further 48 h. All reagents were sterile-filtered, gassed
with argon and added automatically by a PALHTS sample autoprocessor (CTC-PAL
Analytics, Zwingen, Switzerland). Protein hydrolysate (25 ml) was spiked with
isotopic standards ([15N2]arg, 5 nmol and [5-13C-4,4,5,5-2H4]citrulline, 25 pmol;
25 ml) and analysed by LC-MS/MS using an AcquityTM UPLC system with a Quattro
Premier tandem mass spectrometer (Waters, Manchester, U.K.). Samples are
maintained at 4uC in the autosampler during batch analysis. The column was
150 mm 3 2.1 mm HypercarbTM (3 mm particle size; Thermo, Runcorn, U.K.) at
30uC. The mobile phase was 0.1% trifluoroacetic acid (TFA) from 0–5 min and a
linear gradient of 0–2.5% acetonitrile from 5–20 min; the flow rate was 0.2 ml/min.
Eluate was directed to the mass spectrometer from 4–20 min. Analytes were detected
by electrospray positive ionization, multiple reaction monitoring (MRM). The
ionization source and desolvation gas temperatures were 120uC and 350uC,
respectively. The cone gas and desolvation gas flow rates were 100 and 900 l/h,
respectively. The capillary voltage was 3.55 kV. Argon gas (2.7 3 1023 mbar) was in
the collision cell. Programmed molecular ion and fragment ion masses optimized to
60.1 Da and collision energies were and 61 eV for MRM detection. CP contents of
Figure 3 | Citrullinated protein and hydroxyproline in plasma and synovial fluid compartments in early-stage and advanced arthritis. CP:
(a) osteoarthritis and (b) rheumatoid arthritis. Hyp: (c) osteoarthritis and (d) rheumatoid arthritis. Data are median (lower – upper quartile); for eOA, n
5 16; aOA, n 5 17, eRA, n 5 10 and aRA, n 5 22. Lines joint median estimates in plasma/serum to synovial fluid from the same subject groups.
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plasma and synovial fluid protein are normalised to arginine content and given as
mmol/mol arg.
Analysis of 4-hydroxyproline. FreeHypwas analysed in plasma and synovial fluid by
similar method except 25 ml ultrafiltrate, prepared by 3 kDa cut-off microspin filter
with 25 pmol 4,5-[13C2]Hyp, was analysed. 4,5-[13C2]Hyp synthesised as described30
from [13C2]glyoxal31. Hyp concentrations are given in mM.
Other assessments. CCP antibody positivity was assessed by automated enzymatic
immunoassay (EliA CCP; Phadia, Uppsala, Sweden)32.
Statistical analyses. Data are presented as mean 6 SD for parametric distributions
andmedian (lower – upper quartile) for non-parametric distributions. Significance of
the difference between means of parametric data was analysed by Student’s t-test and
between medians of non-parametric data were analysed byMann-Whitney U test for
independent samples andWilcoxon’s signed ranks test for paired samples (analytes of
plasma and synovial fluid of the same donor). Correlation analysis was performed by
the Spearman method. Limit of detection was defined as an analyte amount
equivalent to 3 SD of the zero analyte control deduced from response calibration
curves. Data were analysed using SPSS, version 16.0. For diagnostic algorithm
generation only controls, eOA, eRA and non-RA subject groups were used with data
of age, gender, plasma CP, plasma free hydroxyproline, anti-CCP antibodies and RF.
For each subject group and method, four ‘‘Leave-One-Out’’ cross-validations were
performed and feature selection used to identify which of the features were
informative biomarkers. Three different machine learning algorithms were used:
Random Forests - a nonlinear, tree-basedmethod9, stepwise generalized linear model
(GLM) and generalized linear models with elastic net (GLMNET)10. The latter uses a
sparse form of logistic regression, where it is assumed that parameters for some input
variables will be exactly zero (and hence they do not contribute to the analysis). For
this we use the R package ‘glmnet’. The 95% CI are determined via bootstrap analysis,
using the R package ‘‘pROC’’33. Significance of the 4-class algorithm outcome was
assessed by exact binomial test for the null hypothesis that predicted classes are
assigned randomly, probability 0.25.
1. Connelly, L. B., Woolf, A. & Brooks, P. [Cost-effectiveness of interventions for
musculoskeletal conditions]. Disease Control Priorities in Developing Countries
[Jamieson, D. T. et al. (eds.)] [963–980] (World Bank, Washington DC, 2006).
2. Menashe, L. et al. The diagnostic performance of MRI in osteoarthritis: a
systematic review and meta-analysis.Osteoarthritis & Cartilage 20, 13–21 (2012).
3. Raza, K. et al. Predictive value of antibodies to cyclic citrullinated peptide in
patients with very early inflammatory arthritis. J. Rheumatol. 32, 231–238 (2005).
4. Van Venrooij, W. J., Van Beers, J. J. B. C. & Pruijn, G. J. M. Anti-CCP antibody, a
marker for the early detection of rheumatoid arthritis. Ann. N.Y. Acad. Sci. 1143,
268–285 (2008).
5. Van Venrooij, W. J., van Beers, J. J. B. C. & Pruijn, G. J. M. Anti-CCP antibodies:
the past, the present and the future. Nature Rev. Rheumatol. 7, 391–398 (2011).
6. Seibel, M. J. Biochemical markers of bone turnover: part I: biochemistry and
variability. Clin. Biochem. Rev. 26, 97–122 (2005).
7. Weaver, C. M. et al. Quantification of biochemical markers of bone turnover by
kinetic measures of bone formation and resorption in young healthy females.
J. Bone & Mineral Res. 12, 1714–1720 (1997).
8. Takizawa, Y. et al. Citrullinated fibrinogen detected as a soluble citrullinated
autoantigen in rheumatoid arthritis synovial fluids. Ann. Rheumatic Dis. 65,
1013–1020 (2006).
9. Breiman, L. Random Forests. Machine learning 45, 5–32 (2001).
10. Friedman, J., Hastie, T. & Tibshirani, R. Regularization Paths for Generalized
Linear Models via Coordinate Descent. J. Statistical Software 33, 1–22 (2010).
11. Rokach, L. Ensemble-based classifiers. Artif. Intell. Rev. 33, 1–39 (2010).
12. Rousseau, J. C. & Garnero, P. Biological markers in osteoarthritis. Bone 51,
265–277 (2012).
13. Sohn, D. et al. Plasma proteins present in osteoarthritic synovial fluid can
stimulate cytokine production via Toll-like receptor 4. Arthritis Research &
Therapy 14, R7 (2012).
14. Abramson, S. B. & Attur, M. Developments in the scientific understanding of
osteoarthritis. Arthritis Research & Therapy 11, 227–236 (2009).
15. Foulquier, C. et al. Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not
PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in
close association with tissue inflammation. Arthritis & Rheumatism 56,
3541–3553 (2007).
16. Carames, B., Taniguchi, N., Otsuki, S., Blanco, F. J. & Lotz, M. Autophagy is a
protective mechanism in normal cartilage, and its aging-related loss is linked with
cell death and osteoarthritis. Arthritis & Rheumatism 62, 791–801 (2010).
17. Scott, I. C. et al. Predicting the risk of rheumatoid arthritis and its age of onset
through modelling genetic risk variants with smoking. PLoS Genet 9, e1003808
(2013).
18. Sokolove, J. et al. Autoantibody epitope spreading in the pre-clinical phase
predicts progression to rheumatoid arthritis. PLoS ONE 7, e35296 (2012).
19. Harre, U. et al. Induction of osteoclastogenesis and bone loss by human
autoantibodies against citrullinated vimentin. J. Clin. Invest. 122, 1791–1802
(2012).
20. Curis, E. et al. Almost all about citrulline in mammals. Amino Acids 29, 177–205
(2005).
21. Thornalley, P. J. & Rabbani, N. Detection of oxidized and glycated proteins in
clinical samples usingmass spectrometry - A user’s perspective. Biochim. Biophys.
Acta 1840, 818–829 (2014).
22. De Ceuleneer, M., Van Steendam, K., Dhaenens, M. & Deforce, D. In vivo
relevance of citrullinated proteins and the challenges in their detection.
Proteomics 12, 752–760 (2012).
23. Seger, C. &Vogeser,M. [Pitfalls of LC-MS/MS in the clinical laboratory] LC-MS in
Drug Bioanalysis [Xu, Q. A. & Madden, T. L. (eds.)] [109–126] (Springer: New
York, 2012).
24. Roth,M. Fluorimetric determination of free hydroxyproline and proline in blood-
plasma. Clin. Chim. Acta 83, 273–277 (1978).
25. Inoue, H., Iguch, H., Kouno, A. & Tsuruta, Y. Fluorometric determination of N-
terminal prolyl dipeptides, proline and hydroxyproline in human serum by pre-
column high-performance liquid chromatography using 4-(5,6-dimethoxy-2-
phthalimidinyl)-2-methoxyphenylsulfonyl chloride. J. Chromatogr. B 757,
369–373 (2001).
26. Manicourt, D., Brauman, H. & Orloff, S. Synovial-fluid beta-2 microglobulin and
hydroxyproline fractions in rheumatoid-arthritis and non-autoimmune
arthropathies. Ann. Rheumatic Dis. 39, 207–216 (1980).
27. Wenham, C. Y. J. & Conaghan, P. G. The role of synovitis in osteoarthritis.
Therapeutic Advances in Musculoskeletal Disease 2, 349–359 (2010).
28. Gasser, A. B., Wootton, R., Beyeler, S., Celada, A. & Depierre, D. Biological
variation in free serum hydroxyproline concentration. Clin. Chim. Acta 106,
39–43 (1980).
29. Rabbani, N., Shaheen, F., Anwar, A., Masania, J. & Thornalley, P. J. Assay of
methylglyoxal-derived protein and nucleotide AGEs. Biochem. Soc. Trans. 42,
511–517 (2014).
30. Ramaswamy, S. G. & Adams, E. One vessel synthesis of 4-hydroxyproline from
glyoxal and oxaloacetic acid. J. Org. Chem. 42, 3440–3442 (1977).
31. Thornalley, P. J. & Rabbani, N. Assay of methylglyoxal and glyoxal and control of
peroxidase interference. Biochem. Soc. Trans. 42, 504–510 (2014).
32. Bizzaro, N., Tonutti, E., Tozzoli, R. & Villalta, D. Analytical and Diagnostic
Characteristics of 11 2nd- and 3rd-generation immunoenzymaticmethods for the
detection of antibodies to citrullinated proteins. Clin. Chem. 53, 1527–1533
(2007).
33. Robin, X. et al. pROC: an open-source package for R and S plus to analyze and
compare ROC curves. BMC Bioinformatics 12, 77–85 (2011).
Author contributions
U.A., A.A., J.T., N.M., P.J.T. and N.R. acquired the data, U.A., R.S.S., M.L.C., A.F., K.R.,
R.A.W., P.G.W., R.C.H., P.J.T. and N.R. analysed and interpreted the data, U.A., R.S.S.,
P.J.T. and N.R. drafted the report and all authors reviewed and revised it critically and
approved the final version to be published.
Additional information
Supplementary information accompanies this paper at http://www.nature.com/
scientificreports
Competing financial interests: No authors have any competing interests apart from U.A.,
R.S., P.J.T. and N.R., they published a patent on this work (international publication
number: WO2014016584).
How to cite this article: Ahmed, U. et al. Biomarkers of early stage osteoarthritis,
rheumatoid arthritis and musculoskeletal health. Sci. Rep. 5, 9259; DOI:10.1038/srep09259
(2015).
This work is licensed under a Creative Commons Attribution 4.0 International
License. The images or other third party material in this article are included in the
article’s Creative Commons license, unless indicated otherwise in the credit line; if
the material is not included under the Creative Commons license, users will need
to obtain permission from the license holder in order to reproduce thematerial. To
view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 5 : 9259 | DOI: 10.1038/srep09259 7
